MX2016006197A - Formulaciones de compuestos de azaindol. - Google Patents
Formulaciones de compuestos de azaindol.Info
- Publication number
- MX2016006197A MX2016006197A MX2016006197A MX2016006197A MX2016006197A MX 2016006197 A MX2016006197 A MX 2016006197A MX 2016006197 A MX2016006197 A MX 2016006197A MX 2016006197 A MX2016006197 A MX 2016006197A MX 2016006197 A MX2016006197 A MX 2016006197A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- pharmaceutical composition
- salt
- composition comprises
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporciona una composición farmacéutica que comprende: a) 5% en peso a 95% en peso de una sal de HCl del compuesto (1) ·?H2O por el peso de la composición farmacéutica, en donde x es 0 a 3; y b) 5% en peso a 95% en peso de un material de relleno por el peso de la composición farmacéutica. Otra composición farmacéutica comprende: a) 1 mg/ml a 20 mg/ml del compuesto (1) en agua; y b) 0.01 M a 0.1 M de un modificador de pH farmacéuticamente aceptable. Un método de preparación de una composición farmacéutica, que comprende proporcionar una mezcla del compuesto (1) que incluye la sal de HC1 del compuesto (1) ·?H2O y el material de relleno. Otro método de preparación de una composición farmacéutica comprende la sal de HC1 del compuesto (1) ·?3/4O y el modificador de pH para formar 1 mg/ml a 20 mg/ml del compuesto (1) en agua. Se describen métodos para reducir la cantidad de virus de influenza, inhibir la replicación de virus de influenza y tratar influenza, cada uno utiliza independientemente estas composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361903840P | 2013-11-13 | 2013-11-13 | |
| PCT/US2014/065144 WO2015073491A1 (en) | 2013-11-13 | 2014-11-12 | Formulations of azaindole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016006197A true MX2016006197A (es) | 2016-08-08 |
Family
ID=52001095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006197A MX2016006197A (es) | 2013-11-13 | 2014-11-12 | Formulaciones de compuestos de azaindol. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20160250213A1 (es) |
| EP (1) | EP3068434A1 (es) |
| JP (2) | JP2016537347A (es) |
| KR (1) | KR20160084465A (es) |
| CN (1) | CN105848683A (es) |
| AU (1) | AU2014348762A1 (es) |
| CA (1) | CA2930105A1 (es) |
| CL (1) | CL2016001111A1 (es) |
| IL (2) | IL245587A0 (es) |
| MX (1) | MX2016006197A (es) |
| RU (1) | RU2685730C1 (es) |
| SG (1) | SG10201804024VA (es) |
| WO (1) | WO2015073491A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120508A1 (es) | 2009-06-17 | 2012-05-09 | Vertex Pharma | Inhibidores de la replicacion de los virus de la gripe |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| SI3421468T1 (sl) | 2013-11-13 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Postopki za pripravo inhibitorjev replikacije virusov influence |
| SG10201804026WA (en) | 2013-11-13 | 2018-06-28 | Vertex Pharma | Inhibitors of influenza viruses replication |
| WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| EP3294735B8 (en) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| AU2016368317B2 (en) | 2015-12-09 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| CN107759571B (zh) | 2016-08-16 | 2021-03-02 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| WO2018041091A1 (en) | 2016-08-30 | 2018-03-08 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| CA3045371C (en) * | 2016-12-15 | 2024-05-14 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| CN108276401B (zh) | 2017-01-05 | 2020-12-22 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| US10815232B2 (en) | 2017-01-24 | 2020-10-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereof |
| WO2018157830A1 (en) | 2017-03-02 | 2018-09-07 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| JP2020516634A (ja) * | 2017-04-12 | 2020-06-11 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルス感染の処置方法および併用療法 |
| US11844864B2 (en) * | 2017-08-31 | 2023-12-19 | Novartis Ag | Method for preparing granules |
| EP3774794A1 (en) * | 2018-04-06 | 2021-02-17 | Janssen Pharmaceuticals, Inc. | Isothermal reactive crystallisation process for the preparation of a crystalline form of pimodivir hydrochloride hemihydrate |
| WO2020058745A1 (en) * | 2018-09-18 | 2020-03-26 | Shionogi & Co., Ltd. | Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof |
| BR112021009254A2 (pt) * | 2018-11-13 | 2021-08-10 | Cocrystal Pharma, Inc. | formulações para produtos terapêuticos para influenza |
| KR20200106607A (ko) * | 2019-03-05 | 2020-09-15 | 주식회사 코아팜바이오 | 오셀타미비르 함유 의약 조성물 |
| US20200397784A1 (en) * | 2019-06-20 | 2020-12-24 | Janssen Pharmaceuticals, Inc. | Formulations of azaindole compounds |
| CN112578034B (zh) * | 2020-11-04 | 2022-02-11 | 广东众生睿创生物科技有限公司 | 一种手性胺小分子及其盐的质量控制方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681815A (en) * | 1993-06-28 | 1997-10-28 | Sophie Chen | Antiviral and antitumor agents |
| PL2522365T3 (pl) * | 2004-11-24 | 2017-05-31 | Meda Pharmaceuticals Inc. | Kompozycje zawierające azelastynę i sposoby ich zastosowania |
| US20120093738A1 (en) * | 2009-06-11 | 2012-04-19 | Rubicon Research Private Limited | Taste-masked oral formulations of influenza antivirals |
| PE20120508A1 (es) * | 2009-06-17 | 2012-05-09 | Vertex Pharma | Inhibidores de la replicacion de los virus de la gripe |
-
2014
- 2014-11-12 CA CA2930105A patent/CA2930105A1/en not_active Abandoned
- 2014-11-12 RU RU2016122609A patent/RU2685730C1/ru active
- 2014-11-12 AU AU2014348762A patent/AU2014348762A1/en not_active Abandoned
- 2014-11-12 WO PCT/US2014/065144 patent/WO2015073491A1/en not_active Ceased
- 2014-11-12 SG SG10201804024VA patent/SG10201804024VA/en unknown
- 2014-11-12 EP EP14805749.0A patent/EP3068434A1/en not_active Withdrawn
- 2014-11-12 JP JP2016529960A patent/JP2016537347A/ja active Pending
- 2014-11-12 KR KR1020167015721A patent/KR20160084465A/ko not_active Ceased
- 2014-11-12 CN CN201480071163.7A patent/CN105848683A/zh active Pending
- 2014-11-12 MX MX2016006197A patent/MX2016006197A/es unknown
-
2016
- 2016-05-10 US US15/150,497 patent/US20160250213A1/en not_active Abandoned
- 2016-05-10 CL CL2016001111A patent/CL2016001111A1/es unknown
- 2016-05-10 IL IL245587A patent/IL245587A0/en unknown
-
2018
- 2018-07-16 US US16/036,044 patent/US20180318301A1/en not_active Abandoned
-
2020
- 2020-09-30 US US17/038,749 patent/US20210008072A1/en not_active Abandoned
- 2020-10-21 IL IL278214A patent/IL278214A/en unknown
-
2021
- 2021-09-17 JP JP2021152005A patent/JP2021191796A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3068434A1 (en) | 2016-09-21 |
| US20160250213A1 (en) | 2016-09-01 |
| SG10201804024VA (en) | 2018-07-30 |
| RU2016122609A (ru) | 2017-12-18 |
| WO2015073491A1 (en) | 2015-05-21 |
| IL278214A (en) | 2020-11-30 |
| US20180318301A1 (en) | 2018-11-08 |
| CL2016001111A1 (es) | 2017-06-09 |
| US20210008072A1 (en) | 2021-01-14 |
| KR20160084465A (ko) | 2016-07-13 |
| IL245587A0 (en) | 2016-06-30 |
| CA2930105A1 (en) | 2015-05-21 |
| CN105848683A (zh) | 2016-08-10 |
| JP2021191796A (ja) | 2021-12-16 |
| AU2014348762A1 (en) | 2016-05-26 |
| JP2016537347A (ja) | 2016-12-01 |
| RU2685730C1 (ru) | 2019-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016006197A (es) | Formulaciones de compuestos de azaindol. | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| PH12017500281A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| PH12018500147A1 (en) | Benzodiazepine derivatives as rsv inhibitors | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| MY176246A (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| ZA201805185B (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms | |
| MX2014013851A (es) | Composiciones farmaceuticas topicas que comprenden terbinafina y urea. | |
| MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| MX2013014577A (es) | Compuestos de heteroarilo como ligandos del receptor 5-ht4. | |
| TN2013000533A1 (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| EA201600394A1 (ru) | Трициклические соединения пиперидина | |
| EA201490573A1 (ru) | Соединение бензотиазолона | |
| PH12015502717B1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| MX362905B (es) | Tratamiento de combinacion. | |
| RU2013127794A (ru) | Фармацевтическая комбинация и композиция для лечения ожирения и ее применение | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| EA201891027A1 (ru) | Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение | |
| MX2017005745A (es) | Composiciones antisarro para el cuidado bucal que proporcionan la prevencion de la cristalizacion. |